Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Melanoma × urelumab × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Multiple Myeloma 1 Melanoma 1 Lymphoma, B-Cell 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Colorectal Neoplasms 1 Brain Neoplasms 1 B-Cell Malignancies 1

Interventions

Ipilimumab 100 pembrolizumab 84 aldesleukin 81 Nivolumab 79 Interleukin-2 50 Cyclophosphamide 50 Dacarbazine 47 Vemurafenib 35 trametinib 34 incomplete Freund's adjuvant 33 fludarabine phosphate 32 Temozolomide 32 sargramostim 29 dabrafenib 27 Bevacizumab 23 fludarabine 22 Paclitaxel 21 montanide ISA 51 20 MART-1 Antigen 20 Cisplatin 19 Carboplatin 18 Sorafenib 17 Interferon-alpha 17 Granulocyte-Macrophage Colony-Stimulating Factor 17 atezolizumab 15 Radiosurgery 15 Introns 15 Blood Specimen Collection 15 cobimetinib 14 Filgrastim 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Bristol-Myers Squibb

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡